Reata Pharmaceuticals Inc.’s newly approved treatment for Friedreich’s ataxia will have a wholesale acquisition price of $370,000 per year, the company told...
Reata Pharmaceuticals Inc.’s RETA newly approved treatment for Friedreich’s ataxia will have a wholesale acquisition price of $370,000 per year, the company told investors on Tuesday night. The Food and Drug Administration on Tuesday approved the drug, Skyclarys, which treats a rare nervous-system disease that affects about 4,500 diagnosed patients in the U.S. Reata’s stock was up about 195% in trading on Wednesday afternoon, a day after the FDA approval was announced.
... Reata Pharmaceuticals Inc.’s RETA newly approved treatment for Friedreich’s ataxia will have a wholesale acquisition price of $370,000 per year, the company told investors on Tuesday night. The Food and Drug Administration on Tuesday approved the drug, Skyclarys, which treats a rare nervous-system disease that affects about 4,500 diagnosed patients in the U.S. Reata’s stock was up about 195% in trading on Wednesday afternoon, a day after the FDA approval was announced.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
U.S. FDA approves Reata's rare genetic disorder drugThe U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system, sending shares up nearly 160% after the bell.
Les mer »
Reata’s stock jumps 175% in premarket trading after FDA approvalShares of Reata Pharmaceuticals Inc. soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys,...
Les mer »
Genesis rappelle 65 000 véhicules | Actualités automobile | Auto123Genesis doit rappeler quelque 65 000 véhicules en raison d’un problème avec les ceintures de sécurité. Auto123 a les détails.
Les mer »
FDA approves Reata's rare disease drug amid questions about changes to the regulatory environment for neuroscience treatmentsFDA approves Reata’s rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments
Les mer »
Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operationsHere are U.S. stocks in focus ahead of Wednesday’s trading session.
Les mer »
Record revenue at SandfireMetals miner Sandfire Resources has reported record sales revenue for the half-year ended December, on the back of production and sales contributions from the MATSA operation, in Spain. Sales revenue for the six months to December reached $431.7-million, up from the $311.8-million reported in the previous corresponding period, with copper sales volumes increasing from 32 422 t to 46 005 t and silver sales from 95 000 oz to 870 000 oz.
Les mer »